Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Market

Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. The disease is caused by an absence of dystrophin, a protein that helps keep muscle cells intact.


DMD is caused by changes (mutations) in the DMD gene. The DMD gene codes for the protein dystrophin. Dystrophin is mainly made in skeletal and heart muscle cells, but a small amount is made in nerve cells (neurons) in specific parts of the brain. DMD is inherited in an X-linked recessive pattern and is passed on by the mother, referred to as a carrier; however, it may also occur in people who do not have a family history of DMD. 


Duchenne Muscular Dystrophy Epidemiological Segmentation


The Epidemiological Segmentation of Duchenne Muscular Dystrophy in 7MM from 2018 to 2030 is segmented as:-


  • Total Prevalent Population of Duchenne Muscular Dystrophy
  • Age-specific Prevalent Population of Duchenne Muscular Dystrophy 
  • Ambulatory and Non-ambulatory Population of Duchenne Muscular Dystrophy
  • The mutation-specific prevalent population of Duchenne Muscular Dystrophy 
  • Associated Comorbidities of Duchenne Muscular Dystrophy 


Duchenne Muscular Dystrophy Epidemiology (2020)


  • The total Duchenne Muscular Dystrophy prevalent population in 7MM was 30,688.
  • The total number of DMD prevalent cases in the United Kingdom was found to be 2,622.
  • The total number of Duchenne Muscular Dystrophy prevalent cases in the United States was found to be 16,765.
  • The total Duchenne Muscular Dystrophy prevalent cases in France were 2,101.
  • In Germany, the total number of DMD prevalent cases was observed to be 2,596.
  • The total number of Duchenne Muscular Dystrophy cases in Spain was estimated to be 1,478.


Duchenne Muscular Dystrophy Market


The therapeutic market size of Duchenne Muscular Dystrophy in 7MM in 2020 was USD USD 745.4 million.


Duchenne Muscular Dystrophy Market Drivers


  • Robust Pipeline Activity
  • Upcoming Launches and Approval
  • Newborn Screening of DMD
  • Increasing Awareness Programs


Duchenne Muscular Dystrophy Market Barriers


  • High Treatment Cost
  • Multidisciplinary Care
  • Lack of Treatment Options for non-ambulant DMD patients


Duchenne Muscular Dystrophy Emerging Drugs


The emerging drugs of the DMD market are:


  • PF-06939926
  • Vamorolone
  • Pizuglanstat (TAS-205)
  • Pamrevlumab (FG-3019)
  • SRP-9001
  • Allogeneic Cardiosphere-derived Cells (CAP-1002)
  • DS-5141b
  • Givinostat
  • ATL1102
  • SRP-5051
  • SGT-001


And many more


Duchenne Muscular Dystrophy Key Players


The key players in the DMD market are:


  • Pfizer
  • Santhera Pharmaceuticals/ReveraGen BioPharma
  • Taiho Pharmaceutical
  • FibroGen
  • Sarepta Therapeutics
  • Capricor
  • Daiichi Sankyo
  • Italfarmaco
  • Antisense Therapeutics
  • Sarepta Therapeutics
  • Solid Biosciences 



And many more

Download Infographic